Lidocaine Alleviates Sepsis-Induced Acute Lung Injury in Mice by Suppressing Tissue Factor and Matrix Metalloproteinase-2/9

1. Introduction

Acute lung injury (ALI) caused by sepsis is one of the main causes of death in ICU patients. Unfortunately, therapies to prevent or treat ALI remain elusive. It is urgent to further investigate the pathogenesis of sepsis-induced ALI and find effective strategy.
induced ALI model in mice, leading to a hypercoagulable state in the pulmonary vasculature [3]. TF expressed in the microvasculature acts as a critical initiator of blood coagulation in ALI, while using the neutralizing antibody to inhibit TF before lethal sepsis prevents ALI in baboons [4, 5]. In addition, study found that antithrombin (hirudin) could also have a protective effect on endotoxemia mice by reducing fibrin deposition [6]. These studies indicated that moderate anticoagulation has certain therapeutic effect on sepsis-induced ALI.

Apoptosis signal-regulating kinase (ASK1) is a member of the MAP3K family, which is activated by a number of cellular stressors, such as oxidative stress and inflammatory cytokines [7, 8]. Study found that ASK1 activation could significantly reduce the expression of TF [9], participating in regulation of hemostasis and thrombosis [10]. As the upstream signaling molecule of ASK1, Toll-like receptor 4 (TLR4) plays an important role in the activation of innate immunity, inducing the production of IL-6, TNF-α, and even TF through the p38/NF-κB signaling [11–13]. Thus, inhibition of the TLR4/ASK1 signaling pathway may be beneficial to ALI. Suppressor of cytokine signaling 3 (SOCS3) is an inhibitor of cytokine signaling pathways, which have been found that can negatively regulate the TLR4-mediated signaling pathway [14], and our previous study also found that inducing the overexpression of SOCS3 can inhibit the activation of the TLR4-p38 pathway [15]. Taken together, upregulating SOCS3 expression to inhibit TLR4-ASK1 axis and decrease TF expression may be an effective strategy to alleviate ALI.

Lidocaine is a common amide-type local anesthetic. Recent study indicated that local anesthetics using lidocaine could inhibit LPS-induced tissue factor messenger RNA (TF mRNA) level in endothelial and monocytes, but the underlying mechanism is unclear [16]. Our previous study has shown that lidocaine could upregulate the expression of SOCS3 and inhibit the activation of TLR4 signal, as well as suppress neuroinflammation [17]. Given the above discussion, we hypothesized lidocaine could induce SOCS3 production in the lungs, decreasing TF expression and alleviating LPS-induced ALI.

2. Materials and Methods

2.1. Chemicals and Reagents. Lidocaine was purchased from Hubei Tianyao Pharmaceutical Co. Ltd. LPS (catalog no. L2630) and compound C (catalog no. P5499) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Antibody for SOCS3 (catalog no. ab16030), HIF-1α (catalog no. ab1), and TF (catalog no. ab189483) was purchased from Abcam (Cambridge, MA, USA). Antibody for phosphorylated AMP-activated protein kinase (p-AMPK) (Thr172; catalog no. 2531), phosphorylated ASK1 (catalog no. 3762S), and phosphorylated p38 mitogen-activated protein kinase (p38; Tyr180/Tyr182; catalog no. 9211) was purchased from Cell Signaling Technology (Beverly, MA, USA). Antibody for β-actin (catalog no. A1978) was purchased from Sigma-Aldrich. Fetal bovine serum (FBS) was purchased from Gibco, and other cell culture media and supplements were purchased from KenGen (KenGen Biotech, China). All other reagents were from Sigma-Aldrich (St. Louis, MO, USA).

2.2. Animals and Treatment. Adult male CD-1 mice (18-22 g) were purchased from the Experimental Animal Center at Nanjing Medical University, Nanjing, China. Animals were housed five to six per cage under pathogen-free conditions with soft bedding under controlled temperature (22 ± 2 °C) and a 12 h light/dark cycle (lights on at 8:00 a.m.). Animals were allowed to acclimate to these conditions for at least 3 days before inclusion in experiments. For each group of experiments, the animals were matched by age and body weight. All procedures were conducted in accordance with the guidelines and regulations of the National Institutes of Health (NIH) and were approved by the Ethics Committee of Nanjing Medical University (No. IACUC-1902012).

The model of sepsis-induced ALI was induced by a single intraperitoneal (i.p.) injection of 12.5 mg/kg of LPS in mice as previously described [18, 19]. Mice were randomly divided into 6 groups (n = 12) according to treatment, including control group (Con), LPS group, lidocaine (2 mg/kg)+LPS group, lidocaine (4 mg/kg)+LPS group, and lidocaine (8 mg/kg)+LPS group. For the survival rate and body weight experiments, different concentrations of lidocaine (2, 4, and 8 mg/kg) were intravenous (i.v.) injection into mice through the tail vein every 12 h for 3 consecutive days. For the other experiments, lidocaine (2, 4, and 8 mg/kg) was i.v. injection into mice through the tail vein 30 min before LPS injection.

2.3. Bronchial Alveolar Lavage Fluid (BALF) Collection and Measurement. The methods to collect BALF were described previously [20]. After LPS injection for 12 h, the mice were anesthetized by 1% sodium amobarbital, and the thorax was opened. 500 μL of PBS was injected, retrieved the liquid from the trachea, and repeated three times. The samples were centrifuged at 5000 rpm for 10 min, and the supernatants were collected. The total protein level in BALF was measured by the BCA kit (Thermo Scientific, MA, USA) according to the manufacturer’s protocol.

2.4. Hematoxylin and Eosin (H&E). For the histological analysis, the mice were anesthetized by 1% sodium amobarbital and sacrificed and then quickly collected the lung tissues from mice. The samples were fixed in 10% formalin for 24 h and then dehydrated in a series of graded ethanol and finally embedded in paraffin. Then, microtome sections (4 μm) were cut and stained with hematoxylin and eosin (H&E). Images were taken under a light microscope (Leica, Germany) by two investigators blinded to a group assignment. Six random fields of each lung section were examined.

2.5. Lung Wet-to-Dry Ratio Assay. Lung wet-to-dry ratio was used as an index of lung edema. After LPS injection for 12 h, mice were sacrificed, and the lung tissues (both lobes) were immediately weighed after collection and recorded as wet weight. The lung tissues were then placed into an oven at 60°C for 72 h and weighed as dry weight. Lung wet-to-dry ratio was calculated by dividing the wet by the dry weights.

2.6. Ultrasonic Testing. The mice were anesthetized by 1% sodium amobarbital, and ultrasonic testing was performed by the US GE E9 ultrasonic machine and 11L ultrasonic...
probe. The test method was referred to Lichtenstein DA double blue dot + PLAPS point detection which checks the distribution of the B line and assesses the distribution area of the B line in the scanning area for semiquantitative analysis. In order to correct the measurement bias, a double-blind design was used during the ultrasonic detection. Neither the investigators nor the sonographers were aware of the type of the mouse group. Each mouse underwent ultrasonic detection for three times, and the detection was repeated by two sonographers with more than 3 years' experience. The average values of the two measurements were statistically analyzed.

2.7. Cell Cultures. Human mononuclear macrophages (THP-1, No. ZQ 0086) were purchased from the Shanghai Zhongqiao Biological Research Institute, China, and maintained in humidified 5% CO2 at 37°C in Dulbecco's modified Eagle's Medium (DMEM; KenGen Biotech, China) supplemented with 10% (v/v) FBS, penicillin (100 U/mL), and streptomycin (100 μg/mL). For further experiments, 105 cells were plated in a 6-well plate overnight and then treated with LPS (100 ng/mL) in the following morning with or without lidocaine for 12 h. Cell extracts and precipitated supernatants were collected and analyzed by immunoblot assay.

2.8. Gelatin Zymography. Mice were anesthetized with 1% sodium amobarbital and then collected blood samples, and the red blood cell lysis buffer (Sigma-Aldrich, MO, USA) was added into the blood for 20 min, after centrifugation (1000 r/min, 5 min) and collected the cells, then added the 1% BSA into the cells, and centrifugation (1000 r/min) again for 5 min, and then the cells were collected and stained with monoclonal anti-mouse antibodies: CD45-PE, CD11b-APE, and Ly6G. Cells were stained for 40 min on ice before being washed and analyzed on a FACSVerse flow cytometer (BD, NJ, USA) using FlowJo V10.0.7 (Tree Star, Ashland, USA). CD45+ CD11b+ Ly6G+-positive cells were considered neutrophils.

2.11. Statistical Analyses. GraphPad Prism 6 software (GraphPad Software, San Diego, CA) was used to conduct all the statistical analyses. Kaplan-Meier survival analysis was completed using the log rank (Mantel-Cox) test. Data were statistically evaluated by one-way or two-way analysis of variance (ANOVA) followed by the Bonferroni post hoc tests. Results were represented as the mean ± SEM of three independent experiments. Results described as significant were based on a criterion of P < 0.05.

3. Results

3.1. Lidocaine Significantly Alleviates LPS-Induced ALI. As shown in Figure 1(a), mice administered with LPS (12.5 mg/kg, i.p.) showed decreased survival (20%) on the 7th day as compared to the control group (100%), whereas preadministration of lidocaine (8 mg/kg, i.v.) could significantly increase LPS-treated mouse survival rate. Besides, compared with the LPS group, preadministration of lidocaine (8 mg/kg, i.v.) could also increase the weight of mice from 24.4 ± 0.52 g to 26.43 ± 1.11 g (Figure 1(b)). Moreover, it was found that LPS stimulation for 12 h significantly increased the ratio of wet-to-dry weight of mouse lung tissues from 4.52 ± 0.06 to 6.52 ± 0.76 (Figure 1(c)), and the B-mode ultrasound imaging also indicated that LPS significantly induce pulmonary edema in mice (Figure 1(d)), whereas these effects could be reversed by lidocaine (Figures 1(c) and 1(d)). Further study has found that in i.v. injection of 8 mg/kg of lidocaine into mice for 12 h, the plasma drug concentration reached the lung tissue of 370.3 ± 94.3 ng/mL (Figure S1 and Table S1). In addition, through total protein quantification and flow cytometry detection, it was found that the total protein content in BALF and the number of neutrophils in the blood of LPS-treated mice were significantly increased, and these effects could be reversed by lidocaine (Figures 1(e) and 1(g)), indicating that lidocaine could alleviate LPS-induced severe alveolar leakage. These data suggested that lidocaine could significantly alleviate sepsis-induced ALI.

3.2. Lidocaine Ameliorates LPS-Induced Pulmonary Coagulopathy. Many clinical studies showed that virtually most of septic patients had coagulation abnormalities. Therefore, in this study, we intend to investigate the effect of lidocaine on pulmonary coagulation function induced by LPS in mice. As shown in Figure 2(a), LPS obviously induced the production of thrombotic plaques in the lung tissue of mice, while preadministration of lidocaine (8 mg/kg, i.v.) could significantly reduce
Figure 1: Continued.
the formation of thrombus. In addition, compared with the LPS group, B-mode ultrasound detection also showed that lidocaine (8 mg/kg, i.v.) could increase the blood flow velocity in the subclavian artery in mice (Figure 2(b)). The hematoxylin and eosin (H & E) staining results demonstrated that LPS significantly induced lung tissue structural imperfection and alveolar wall thickening. Furthermore, many thrombi obstructing the pulmonary vasculature were visible in the histological sections, whereas lidocaine significantly ameliorated histopathological damage and reduced the production of pulmonary

**Figure 1**: Lidocaine significantly alleviated sepsis-induced acute lung injury. Survival rate (a) and body weight (b) of mice were measured every day for 7 consecutive days (n = 12 of each group). (c) Wet/dry weight of mouse lung tissues was measured 12 h after intraperitoneal (i.p.) injection of 12.5 mg/kg LPS to mice. (d) Representative images of B-mode ultrasound. Normal mice show an “A” line, while “B” line indicates pulmonary edema in mice. (e) Total protein concentration in bronchoalveolar lavage fluid (BALF). (f) Neutrophil proportion in the blood assessed by flow cytometric analysis. (g) Quantitative data of the neutrophil proportion analyzed by flow cytometry. (n = 4 of each group). Significant difference was revealed following one-way or two-way ANOVA (*P < 0.05, **P < 0.01, and ***P < 0.001 vs. control; #P < 0.05, ##P < 0.01, and ###P < 0.001 vs. LPS-treated group; Bonferroni post hoc tests).

**Figure 2**: Lidocaine markedly ameliorated LPS-induced pulmonary coagulopathy. (a) Representative photographs of lung tissues 12 h after LPS injection. (b) Quantitative data of blood flow velocity in the subclavian artery. (c) Hematoxylin- and eosin-stained (HE) sections of the lung tissues of mice. Black arrow indicated thrombi. Magnifications: 100x and 400x (n = 3 of each group). Significant difference was revealed following one-way ANOVA (**P < 0.001 vs. control; #P < 0.05 vs. LPS-treated group; Bonferroni post hoc tests).
thrombosis (Figure 2(c)). Altogether, these results suggested that lidocaine could ameliorate LPS-induced pulmonary coagulation disorders.

3.3. Lidocaine Could Inhibit TF Expression and MMP-2/9 Activity Induced by LPS in Plasma. Previous studies have found that the circulating blood in patients with sepsis presents a hypercoagulable state [21], and Shaver et al. have also found that the severity of LPS-induced ALI is positively correlated with the level of TF in the circulating blood in mice [22]. In this study, we detected TF expression and MMP-2/9 activity in the plasma of LPS-treated mice. As shown in Figures 3(a) and 3(b), compared with the control group, LPS (12.5 mg/kg, i.p.) significantly increased the expression level of TF, up to 6.6-fold, and the activities of MMP-2/9 in plasma were increased up to 2.92-fold and 3.33-fold, respectively, whereas preadministration of lidocaine (4 and 8 mg/kg, i.p.) could reverse the LPS-induced upregulation of TF and MMP-2/9 in mice (Figures 3(a) and 3(b)). In addition, lidocaine (8 mg/kg) could also significantly reduce the activity of MMP-2/9 in BALF of LPS-treated mice from 19.97-fold to 3.37-fold and from 13.76-fold to 5.87-fold, respectively (Figures 3(c) and 3(d)).

3.4. Lidocaine Could Significantly Inhibit LPS-Induced TF Expression and MMP-2/9 Activity in the Lungs. We further investigated the signaling pathway of the LPS-induced high level of TF and MMP-2/9 in mice. It has been reported that ASK1 is crucial for the formation of thrombus [10], and ASK1 activation may also increase the transcription level of TF mRNA through the MAPK signaling [3]. Compared with the LPS group, LPS could significantly induce the upregulation of p-ASK1 and p-p38 in the lungs of mice up to 2.45-fold and 2.87-fold, respectively, while lidocaine (4 and 8 mg/kg, i.p.) significantly inhibited the activation of ASK1 and p38 (Figures 4(a) and 4(b)). In addition, LPS could also induce the expression of TF, HIF-1α, and MMP-2/9 in the lungs, whereas preadministration with 4 or 8 mg/kg of lidocaine could significantly inhibit these effects (Figures 4(c) and 4(f)). These data suggested that lidocaine could decrease the expression of TF, HIF-1α, and MMP-2/9 by inhibiting the ASK1-p38 signaling pathway.
3.5. Lidocaine Significantly Increased the Expression of p-AMPK and SOCS3 In Vitro and In Vivo. Our previous studies showed that lidocaine could induce the expression of SOCS3 and inhibit neuroinflammation in an AMPK-dependent manner [17]. Therefore, we also investigated whether lidocaine could activate AMPK and induce the production of SOCS3 in lung tissues of mice in vivo. Different concentrations of lidocaine (2, 4, and 8 mg/kg) were administered to mice; data showed that lidocaine (4 and 8 mg/kg) significantly activated AMPK and induced SOCS3 expression in vivo (Figures 5(a) and 5(b)). Moreover, we also performed corresponding experiments on THP1 cells in vitro.

![Western Blot Images](image)

**Figure 4:** Lidocaine significantly inhibited LPS-induced expression of tissue factor (TF) and matrix metalloproteinase (MMP)-2/9 in the lung tissues from mice. Representative Western blot images showed the levels of p-ASK1 (a), p-p38 (b), TF (c), and HIF-1α (d) in lung tissues. (e, f) Activity of MMP-2/9 in lung tissues was measured by gelatin zymography, and the densitometry values were normalized. Mice were treated with different dosages of lidocaine (2, 4, and 8 mg/kg, i.v.) 30 min before LPS injection, and the tissue samples (n = 4 of each group) were collected 12 h after LPS given. Significant difference was revealed following one-way or two-way ANOVA (*P < 0.05, **P < 0.01, and ***P < 0.001 vs. control; #P < 0.05 and ##P < 0.01 vs. LPS-treated group; Bonferroni post hoc tests).

3.6. Lidocaine Protects against LPS-Induced Inflammation via the AMPK/SOCS3 Signaling Pathway. We further conducted experiments on THP1 cells to investigate whether upregulation of AMPK/SOCS3 could inhibit the acute inflammation response induced by LPS. In THP1 cells in vitro, as shown in Figures 6(a) and 6(b), compared with THP1 cells were treated with different concentrations of lidocaine (from 0.01 to 50 μM) for 12 h. As shown in Figures 5(c) and 5(d), lidocaine significantly increased the expression of p-AMPK and SOCS3 in a concentration-dependent manner in vitro. THP1 cells were treated with different dosages of lidocaine (2, 4, and 8 mg/kg, i.v.) 30 min before LPS injection, and the tissue samples (n = 4 of each group) were collected 12 h after LPS given. Significant difference was revealed following one-way or two-way ANOVA (*P < 0.05, **P < 0.01, and ***P < 0.001 vs. control; #P < 0.05 and ##P < 0.01 vs. LPS-treated group; Bonferroni post hoc tests).
**Figure 5:** Lidocaine significantly induced expression of p-AMPK and SOCS3 both in vivo and in vitro. (a, b) Representative Western blot images showed the levels of p-AMPK and SOCS3 in lung tissues from mice given different dosages of lidocaine (2, 4, and 8 mg/kg, i.v.) 30 min before LPS injection (n = 4 of each group). (c, d) Representative Western blot bands have shown the level of p-AMPK and SOCS3 in THP1 cells cultured with different concentrations of lidocaine for 6 h. Significant difference was revealed following one-way ANOVA (*P < 0.05 and **P < 0.01 vs. control; Bonferroni post hoc tests).

the control group, the expression level of TF induced by LPS (100 ng/mL) was increased approximately 2-fold, and the activities of MMP-2/9 were increased nearly 15.7-fold and 5.6-fold, respectively. Moreover, THP1 cell pretreatment with lidocaine (50 μM) for 6 h could increase the expression level of p-AMPK and SOCS3 in vitro (Figures 6(c) and 6(d)), whereas preadministration of AMPK inhibitor (compound C, 10 μM) 30 min before LPS stimulation could significantly reduce the expression level of p-AMPK and SOCS3 from 2.01 ± 0.08-fold to 1.35 ± 0.11-fold and from 2.01 ± 0.14-fold to 1.20 ± 0.18-fold, respectively (Figures 6(c) and 6(d)). Besides, lidocaine also effectively decreased the expression of p-ASK1, p-p38, and TF and the activity of MMP-2/9, while pretreatment with compound C (10 μM) could abolish the inhibition of lidocaine on these proteins (Figures 6(e)–6(i)).

**4. Discussion**

In this study, we found that lidocaine could increase the survival rate and weight of LPS-treated mice and reduce the pulmonary edema. We also found that lidocaine could significantly reduce the formation of pulmonary thrombosis in LPS-treated mice, increase blood flow velocity in the subclavian artery, and ameliorate the histopathological damage. Further research show that lidocaine could significantly inhibit the LPS-induced activation of the ASK1-p38-TF/MMP-2/9 signaling pathway in vivo and in vitro, which depends on AMPK-SOCS3 axis. These results indicated that lidocaine may alleviate sepsis-induced ALI by activating AMPK-SOCS3 axis to inhibit the ASK1-p38-TF/MMP-2/9 signaling pathway.

Acute lung injury (ALI) was first defined in 1967 [23] and characterized as excessive pulmonary inflammation, alveolar-capillary barrier disruption, and pulmonary edema [24]. Numerous studies have demonstrated that in the early stages of infection-induced sepsis ALI, circulating neutrophils infiltrate the lung interstitial and the alveolar cavity to clear microbial pathogens; however, sustained large neutrophil infiltrations could also exacerbate lung damage [25, 26]. There have also been reported that neutrophils have been detected in BALF of acute respiratory distress syndrome (ARDS)/ALI patients, and the number of neutrophils is positively correlated with the severity of lung injury prognosis [27, 28], and the conditional knockout of neutrophils in LPS-treated mice could significantly reduce pulmonary edema and improve ALI [29]. In this study, we also found that the total protein content in BALF was significantly increased in LPS-treated mice (Figure 1(e)), and a large number of neutrophils were detected in the blood (Figures 1(f) and 1(g)). Besides, pathological tissue section results also found that a
Figure 6: Continued.
large number of neutrophils in fli
trated into the lung intersti-
tial; interestingly, these e
fects could be reversed by lidocaine (Figure 2(c)). Study showed that neutrophils could release a large number of inflammatory cytokines and MMPs [30]. MMPs are one of the endopeptidases that could specifically degrade extracellular matrix and chemical or physical barriers,
such as blood-brain barrier and vascular nerve barrier. Our previous study found that paraquat could significantly increase the activity of MMP-9 in the lung tissue of mice [29], and evidences have also shown that MMP-9 could in turn exacerbate lung damage [31]. In this study, we also found that the activity of MMP-2/9 was increased in the plasma, BALF, and lung tissue of LPS-treated mice (Figures 3(b), 3(c), and 3(d) and 4(e) and 4(f)), which may be the cause of alveolar capillary barrier disruption and pulmonary edema. Lidocaine that was administrated half an hour earlier could significantly reduce the activity of MMP-2/9 and alleviate pulmonary edema. In addition, it was also found that LPS could significantly increase the activity of MMP-2/9 in THP1 cells in vitro (Figure 6(b)), and these effects could be reversed by lidocaine (Figures 6(h) and 6(i)).

Previous study has indicated that coagulopathy appeared in the circulation of patients with sepsis [32, 33], and clinical autopsy reports have also reported fibrin microthrombus in the alveoli and pulmonary vessels of patients with ARDS [34]. Inflammatory stimuli can induce a hypercoagulable state by inducing TF in monocytes and endothelial cells [35]. TF is responsible for triggering the clotting cascade in a variety of thrombotic disorders, thus using anticoagulants, such as tissue factor pathway inhibitor (TFPI) or antithrombin that may be useful in the treatment of ALI and ARDS. TFPI, as an endogenous inhibitor of TF, could directly inhibit activated factor X and, in a factor-dependent manner, produce feedback inhibition of the factor VIIa/TF complex. Evidences also indicated that the lower levels of TFPI are strongly correlated with organ dysfunction as well as worse outcome of severe sepsis [36]. However, activated MMP-9 can degrade TFPI, resulting in the imbalance between TF and TFPI [37]. In addition, the formation of thrombus in the microvascular circulation could also induce the increase of HIF-1α expression [38–40], and studies have found that HIF-1α can also mediate the expression of MMP-9 [41]. These would further aggravate sepsis-induced ALI by forming a vicious cycle. In this study, our results showed that LPS could induce the formation of pulmonary thrombosis in LPS-treated mice and reduce blood flow velocity in the subclavian artery, whereas this effect could be abolished by lidocaine (Figures 2(a)–2(c)). Besides, LPS could also significantly increase the expression of TF in the plasma and lung tissues of mice in the model group (Figures 3(a) and 4(c)), and this was also confirmed in THP1 cells in vitro (Figures 6(a) and 6(g)). However, preadministration of lidocaine significantly reduced the LPS-induced increasing of TF in plasma and lung tissue (Figures 3(a) and 4(c)) and inhibited the expression of HIF-1α in lung tissue (Figure 4(d)). Altogether, these data show that lidocaine could significantly inhibit the expression of TF and MMP-2/9 induced by LPS and reduce the formation of pulmonary thrombosis.

We further investigated the way how lidocaine exerted anti-inflammatory and anticoagulant effects to reduce ALI caused by sepsis. Previous studies have found that ASK1 is essential for the formation of thrombus, and conditional knockout of ASK1 or the use of pharmacologic inhibitors of ASK1 can significantly prolong the bleeding time of mice [10]. In addition, LPS can also induce the increase of TF expression by mediating the activation of the ASK1-p38 signaling pathway [3]. In this study, we also found that LPS significantly increase the expression of p-ASK1, p-p38, and TF in lung tissue, and preadministration of lidocaine at different concentrations (4 and 8 mg/kg) could inhibit these effects (Figures 4(a)–4(c)). As an important negative regulator of cytokine signaling pathways, SOCS3 plays a vital role in a variety of inflammatory diseases, such as multiple sclerosis [42], experimental autoimmune encephalomyelitis [43], pain [15], and airway inflammation [44]. Moreover, several studies have found that overexpression of SOCS3 could simultaneously inhibit a variety of inflammatory signals, including TLR4, TNF-R, IL-1R, and IL-6R [45, 46]. Additionally, our previous research also indicated that lidocaine could induce the upregulation of SOCS3, and using SOCS3 small interfering RNA to knockdown SOCS3 sufficiently abolished anti-inflammatory effects of lidocaine; besides, we also found that lidocaine induced upregulation of SOCS3 expression in an AMPK-dependent manner [17], and recent studies have also attempted to use the anti-inflammatory cytokines, such as IL-4, IL-10, and IL-13, to inhibit TF expression in monocytes and protect against ALI [47]. In this study, we further investigated whether lidocaine can mediate AMPK activation and SOCS3 expression in LPS-induced acute lung injury model and whether lidocaine can alleviate LPS-mediated pulmonary edema, coagulation dysfunction, and inflammatory response. Our results show that lidocaine could significantly reduce the level of IL-1β, TNF-α, and IL-6 in the serum and lung tissue of LPS-treated mice (Figure S2). Moreover, lidocaine could also significantly induce the expression of p-AMPK and SOCS3 in vitro and in vivo (Figure 5, Figures 6(c) and 6(d), and Figure S3a-c). Meanwhile, preadministration of AMPK inhibitor (compound C) could reduce the expression of p-AMPK and SOCS3 (Figures 6(c) and 6(d) and Figure S3a-c) and abolish the inhibition of lidocaine on ASK1, p38, and TF in vitro (Figures 6(c)–6(g) and Figure S3d-f). Taken together, these results indicate that lidocaine may promote the expression of SOCS3 in an AMPK-dependent manner, inhibiting the activation of the ASK1-p38-TF/MMP-2/9 signaling pathway to decrease the formation of thrombus and to alleviate sepsis-induced ALI (Figure 7).

In conclusion, we provided the experimental evidence that lidocaine could alleviate sepsis-induced ALI via activating AMPK/SOCS3 axis to inhibit the ASK1-p38-TF/MMP-2/9 signaling pathway to decrease the formation of thrombus and to alleviate sepsis-induced ALI (Figure 7). In the ALI.

Data Availability
The data used to support the findings of this study are available from the corresponding authors with reasonable request.

Conflicts of Interest
The authors declare no conflict of interest.

Authors’ Contributions
B.B.Z., H.B.Y., J.N.Z., and X.L.W. performed the experiments and analyzed the results. B.B.Z., Q.L., H.S., and X.L.W. carried
out the animal experiments, gelatin zymography, and H&E staining. J.N.Z., Q.L.P., and W.T.L. carried out the Western blotting analysis. L.P.J., F.H., Y.S., and X.M.H. helped carry out the cell cultures. Y.L.T. helped revise the manuscript. X.M.H., Y.X.F., and X.Z. conceived the study and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript. Binbin Zheng, Hongbo Yang, Jianan Zhang, and Xueli Wang contributed equally to this work.

Acknowledgments

The authors would like to thank Dr. Xue-Feng Wu for helping us revise the manuscript. This study was supported by the National Natural Science Foundation of China (No. 81971047), the Key R&D Program of Jiangsu Province (Social Development) (No. BE2019732), the Nanjing Municipal Health Science and Technology Development Special Fund Project (YKK19170), the Lianyungang 2020 COVID-19 Emergency Science and Technology Special Fund (No. SF2016), the Nanjing Pharmaceutical Association-Pharmaceutical Research Fund of Changzhou Siyao Hospital (2020YX019), and a grant from the Jiangsu Research Hospital Association for Precision Medication (JY202006).

Supplementary Materials

The supplementary material for this article can be found online. Figure S1: the plasma drug concentration of lidocaine at various time points. Figure S2: lidocaine significantly suppressed LPS-induced inflammatory response in mice. Figure S3: lidocaine alleviated sepsis-induced acute lung injury via activating AMPK/SoCS3 axis to inhibit the ASK1-p38-TF/MMP-2/9 signaling pathway in MLE-12 cells in vitro. Table S1: pharmacokinetic variables of lidocaine following i.v. administration of 8 mg/kg of lidocaine for 12 h to mice (mean ± SD, n = 3). (Supplementary Materials)

References


[38] H. Frobøse, S. Groth Rønn, P. E. Heding et al., “Inhibitor of IL-1 induced tissue factor (TF) synthesis and procoagulant activity (PCA) in purified human monocytes by IL-4, IL-10 and IL-13,” *Cytokine*, vol. 8, no. 11, pp. 822–827, 1996.